Heterotopic ossification (HO) is the formation of bone at extra-skeletal sites. Genetic diseases, traumatic injuries, or severe burns can induce this pathological condition and can lead to severe immobility. While the mechanisms by which the bony lesions arise are not completely understood, intense inflammation associated with musculoskeletal injury and/or highly invasive orthopaedic surgery is thought to induce HO. The incidence of HO has been reported between 3% and 90% following total hip arthroplasty. While the vast majority of these cases are asymptomatic, some patients will present decreased range of motion and painful swelling around the affected joints leading to severe immobility. In severe cases, ectopic bone formation may be involved in implant failure, leading to costly and painful revision surgery. The effects of surgical-related intraoperative risk factors for the formation of HO can also play a role. Prophylactic radiation therapy, and anti-inflammatory and biphosphonates agents have shown some promise in preventing HO, but their effects are mild to moderate at best and can be complicated with adverse effects. Irradiation around surgery could decrease the incidence of HO. However, high costs and the risk of soft tissue sarcoma inhibit the use of irradiation. Increased trials have demonstrated that nonsteroidal anti-inflammatory drugs (NSAID) are effective for the prevention of HO. However, the risk of gastrointestinal side effects caused by NSAID has drawn the attention of surgeons. The effect of the selective COX-2 inhibitor, celecoxib, is associated with a significant reduction in the incidence of HO in patients undergoing THA. Bone morphogenetic proteins (BMP) such as BMP2 identified another novel druggable target, i.e., the remote application of apyrase (ATP hydrolyzing agent) in the burn site decreased HO formation and mitigated functional impairment later. The question is if apyrase can be safely administered through other, such as systematical, routes. While the systemic treatments have shown general efficacy and are used clinically, there may be great benefit obtained from more localised treatment or from more targeted inhibitors of osteogenesis or chondrogenesis. In the surgical setting, prophylaxis for HO is regularly indicated due to the considerable risk of functional impairment. Heterotopic ossification is a well-known complication of total hip arthroplasty, especially when the direct lateral approach is used. Possible intraoperative risks are the size of incision, approach, duration of surgery and gender that can be associated with higher rates of HO or increase of the severity of HO. Like inflammation and tissue damage/ischemia are likely to be the key in the formation of HO, kindness to the soft tissues, tissue preserving surgery, pulse lavage to remove bone inducing factors and avoiding damage to all tissues should be erased as a comorbidity. Incision length, tissue dissection and subsequent localised trauma and ischemia, blood loss, anesthetic type and length of surgery may all contribute to the local inflammatory response. Data suggest that the surgeon may control the extent and nature of HO formation by limiting the incision length and if possible the length of the operation. Currently resection of HO is generally suggested after complete maturation (between 14–18 months), since earlier intervention is thought to predispose to recurrence. Reliable indicators of maturation of HO are diminishing activity on serial bone scans and/or decreasing levels of alkaline phosphatase. Although usually asymptomatic, heterotopic bone formation can cause major disability consisting of pain and a decreased range of motion in up to 7% of patients undergoing THA. Patients benefit from early resection of the heterotopic ossification with a proper and reliable postoperative strategy to prevent recurrence of HO with clinical implications.
Since the market withdrawal of the ASR hip resurfacing in August 2010 because of a higher than expected revision rate as reported in the Australian Joint Replacement Registry (AOAJRR), metal-on-metal hip resurfacing arthroplasty (MoMHRA) has become a controversial procedure for hip replacement. Failures related to destructive adverse local tissue reactions (ALTR) to metal wear debris have further discredited MoMHRA. Longer term series from experienced resurfacing specialists, however, demonstrate good outcomes with excellent 10- to 15-year survivorship in young and active men. Besides, all hip replacement registries report significantly worse survivorship of total hip arthroplasty (THA) in patients under 50 compared to older ages. The triad of a well-designed device, implanted accurately, in the correct patient has never been more critical than with MoMHRA implants. The surgical objectives of MoMHRA were to preserve bone stock, maintain normal anatomy and mechanics of the hip joint and to approximate the normal stress transmission to the supporting femoral bone. The functional objectives were better sports participation, less thigh pain and limp, less perception of a leg length difference and a greater perception of a normal hip. Cobb reported that patients with MoMHRA were able to walk faster and with more normal stride length than patients with well performing hip replacements. They also show that function following hip replacement is very good, with high satisfaction rates, but the use of a patient centered outcome measure (PCOM), and objective measures of function reveal substantial inferiority of THA over MoMHRA in two well-matched groups. When coupled with the very strong data regarding life expectancy and infection, this functional data makes a compelling case for the use of resurfacing in active adults. Recent studies show a possible increase in life expectancy with MoMHRA. Compared with uncemented and cemented total hip replacements, Birmingham hip resurfacing has a significantly lower risk of death in men of all ages. McMinn's investigations additionally suggest a potentially higher mortality rate with cemented total hip replacements. These results have now been confirmed by other centers as well, and confirm that those undergoing MoMHRA have reduced mortality in the long term (up to 10 years) compared with those undergoing THA and that this difference persisted after extensive adjustment for confounding factors. Early revisions were often due to fracture of the femoral neck while later revisions are associated with loosening and/or ALTR to wear debris. In some studies, revisions of MoMHRA with ALTR have been complicated by an increased risk of re-revision and poor outcome. Component malpositioning is the most common cause of MoMHRA failure. Metal ion measurements are an excellent tool to detect wear at an early stage. The revision analysis highlights the importance of surgical experience, indications and prosthesis design. Use of ion levels, big THA-heads and patient education/compliance were identified as factors improving outcome following MoMHRA revision. Today's MoMHRA is conservative to the bone. It is the first implant that proves decrease of wear in time, disappearance of wear in longer term with a possible life time survival of the implant, this unrelated to the activity of the patient. If following an international consensus, the right implant is used, with a perfect technique in the right patient, all benefits exceed the problems described in the past.
Reasons for revision of metal-on-metal hip resurfacing arthroplasty (MoMHRA) have evolved with improving surgical experience and techniques. Early revisions were often due to fracture of the femoral neck while later revisions are associated with loosening and/or adverse local tissue reactions (ALTR) to wear debris. In some studies, revisions of MoMHRA with ALTR have been complicated by an increased risk of rerevision and poor outcome. The purpose of this study was to investigate the causes of failure and to identify factors that improve outcome following revision of a failed HRA. From 2001 to May 2015, 180 consecutive HRA revisions were performed in 172 patients. Ninety-nine primary surgeries were done at a HRA specialist centre (99/4211, revision rate: 2.4%), 81 elsewhere. Eight different HRA designs were revised mainly in females (60%). Components’ orientation was measured from radiographs using EBRA. Ion levels were used as a diagnostic tool since 2006 (n=153). Harris-Hip-Score (HHS) was obtained prerevision and at latest follow-up. The initial experience of the first 42 cases (Initial Group) was compared to cases 43–180 (Later Group). Patients of the Later group were noted to have less soft tissue damage, had significantly bigger THA heads implanted at surgery, were educated of the increased complication risk and some wore an abduction brace for 6 weeks.Background
Methods
Arthroplasty registries and consecutive series indicate significantly worse results of conventional metal-on-polyethylene total hip arthroplasty (THA) in patients younger than 50 years compared to older patients, with inferior clinical outcomes and 10-year survivorship ranging between 70 and 90%. At our institution, patients under 50 needing a THA receive either a metal-on-metal hip resurfacing (MoMHRA) or a ceramic-on-ceramic (CoC)THA. In order to evaluate the outcome of these options at minimum 10 years, we conducted a retrospective review of all MoMHRA and CoCTHA with more than 10 years follow-up implanted in patients under 50. From a single surgeon patients’ prospective database, we identified all consecutive THA performed before May 2005 in patients under 50. All patients are contacted by phone and asked to present for a clinical exam and patient reported outcome questionnaires, standard radiographs and metal ion measurements unless the hip arthroplasty has been revised. Complications and reasons for revision are noted. Kaplan-Meier survivorship is analysed for the whole cohort and sub-analysis is performed by type hip arthroplasty, gender, diagnosis and component size.Background and aim
Methods
Since the market withdrawal of the ASR hip resurfacing in August 2010 because of a higher than expected revision rate as reported in the Australian Joint Replacement Registry (AOAJRR), metal-on-metal hip resurfacing arthroplasty (MoMHRA) has become a controversial procedure for hip replacement. Failures related to destructive adverse local tissue reactions to metal wear debris have further discredited MoMHRA. Longer term series from experienced resurfacing specialists however, demonstrated good outcomes with excellent 10-to-15-year survivorship in young and active men. These results have recently been confirmed for some MoMHRA designs in the AOAJRR. Besides, all hip replacement registries report significantly worse survivorship of total hip arthroplasty (THA) in patients under 50 compared to older ages. The aim of this study was to review MoMHRA survivorship from the national registries reporting on hip resurfacing and determine the risk factors for revision in the different registries. The latest annual reports from the AOAJRR, the National Joint Registry of England and Wales (NJR), the Swedish Hip Registry (SHR), the Finnish Arthroplasty Registry, the New Zealand Joint Registry and the Arthroplasty Registry of the Emilia-Romagna Region in Italy (RIPO) were reviewed for 10-year survivorship of MoMHRA in general and specific designs in particular. Other registries did not have enough hip resurfacing data or long term data yet. The survivorship data were compared to conventional THA in comparable age groups and determinants for success/failure such as gender, age, diagnosis, implant design and size and surgical experience were reviewed.Background and aim
Methods
Systemic levels of metal ions are surrogate markers of in-vivo wear of metal-on-metal hip resurfacings (MoMHRA). The wear-related generation of metal ions is associated with component size and positioning but also with design specific features such as coverage angle, clearance, metallurgy and surface technology. The objective of the study was to investigate whether a hip resurfacing design (ACCIS) with TiNb engineered bearing surfaces would generate less chromium (Cr) and cobalt (Co) ions during and after the run-in phase of wear and whether Ti ions could be detected indicating wear of the coating.INTRODUCTION
OBJECTIVES
Potential systemic toxicity of metal ions from metal-on-metal hip arthroplasties (MoMHA) is concerning. High blood cobalt (Co) levels have been associated with neurological, cardiac and thyroid dysfunctions. The aim of this research was to investigate the prevalence of systemic Co toxicity in a MoMHA population, to identify confounding factors, and to indicate a Co level above which there is a high risk for systemic toxicity.Background:
Questions/purposes:
Metal-on-metal hip resurfacings (MoMHRAs) have a characteristic wear pattern initially characterised by a run-in period, followed by a lower-wear steady-state. The use of metal ions as surrogate markers of in-vivo wear is now recommended as a screening tool for the in-vivo performance of MoMHRAs. The aims of this retrospective study were to measure ion levels in MoMHRAs at different stages during the steady-state in order to study the evolution of wear at minimum 10 years postoperatively and describe factors that affect it. A retrospective study was conducted to investigate the minimum 10-year survivorship of a single-surgeon Birmingham Hip Resurfacing (BHR) series, and the evolution of metal ion levels. Implant survival, Harris Hip Scores (HHS), radiographs and serum metal ion levels were assessed. The evolution of metal ion levels was evaluated in 80 patients for whom at least two ion measurements were available at more than 12 months postoperatively, i.e. past the run-in phase. Ion level change (Delta Cr; Delta Co) was defined as Cr or Co level at last assessment minus Cr or Co level at initial assessment. Sub-analysis was performed by gender, diagnosis, age, femoral component size and cup inclination angle.Introduction
Materials and methods
Metal-on-metal hip resurfacing (MoMHRA) requires a new standardized radiographic evaluation protocol. Evaluation of the acetabular component is similar to total hip arthroplasty but the femoral component requires different criteria since there is no component in the femoral canal and the metallic femoral implant overlies the junctions between bone-cement and cement-prosthesis. Lucencies around the metaphyseal HRA femoral stem can be described with the femoral zonal system into 3 peg-zones (Amstutz' et al) but this doesn't account for bony changes of the femoral neck away from the stem. This study proposes a new femoral zonal system for radiographic HRA assessment. We tested the efficacy of radiographs in identifying a problem by reviewing 711 radiographs of resurfaced hips and correlating radiographic features to outcome. 611 in-situ HRA (one surgeon) with minimum two radiographs at >12 months postoperatively and 100 revised HRA (55 referred) were assessed for component positioning, reactive lines±cortical thickening±cancellous condensation (borderline) and lucent lines±osteolysis±bone resorption (sinister). Findings around the acetabular implant were classified in six zones: Zones I-III equally distributed acetabular zones (DeLee-Charnley); Zone IV, V and VI situated in the iliac, pubic and ischial bone respectively. Findings around the proximal femur are defined with a new zonal system, dividing the implant-cement-bone interfaces and the femoral neck into 7 areas. Zones 1,7 at the superior and inferior part of the femoral neck-head, zones 2,3 at the proximal and distal halves of the superior aspect of the stem, zone 4 at the tip, zones 5,6 at the distal and proximal inferior aspects of the stem). Radiological findings and zones were correlated with gender, size, survival, Harris Hip Scores (HHS), metal ions, and adverse soft tissue reactions (ALTR).INTRODUCTION
METHODS
Hip resurfacing (HRA) designer centres have reported survivorships between 88.5–96% at 12 years. Arthroplasty Registries (AR) reported less favourable results especially in females gender and small sizes. The aim of this study was to evaluate the minimum 10-year survival and outcome of the Birmingham Hip Resurfacing (BHR) from an independent specialist centre. Since 1998, 1967 BHRs have been implanted in our centre by a single hip resurfacing specialist. The first 249 BHR, implanted between 1999 and 2001 in 232 patients (17 bilateral) were included in this study. The majority of the patients were male (163; 69%). The mean age at surgery was 50.6 years (range: 17–76), with primary OA as most common indication (201; 81%), followed by avascular necrosis (23; 9.2%) and hip dysplasia (11; 4.4%). Mean follow up was 10.2 years (range: 0.1 (revision) to 13.1). Implant survival was established with revision as the end point. Harris Hip Scores (HHS), radiographs and metal ion levels were assessed in all patients. Sub-analysis was performed by gender, diagnosis and femoral component size (Small: <50 mm; Large: ≥50 mm).Introduction
Methods
The surgical treatment of young adults with end-stage hip disease has been a challenge. Inferior THA survival in the young, perceived advantages of hip resurfacing versus THA and advancements in tribology, led to the introduction of 3rd generation Metal-on-Metal-Hip-Resurfacing-Arthroplasty (MoMHRA). To-date, thousands of such prostheses have been implanted worldwide in younger patients, yet little is known regarding long-term outcome. The only studies reporting greater than 10 year outcome come from designer centres with survivorship varying between 88.5–96% at 12 years. Arthroplasty Registries (AR) have reported less favourable survivorships with female gender and size having a negative effect on survival. In our independent hip resurfacing centre in Ghent, Belgium, a single surgeon has implanted more than 3500 HRA over more than 12 years. A cohort of 149 patients who received a Birmingham Hip Resurfacing (BHR) at a mean age of 50 years at surgery have now reached a minimum 10 years follow-up. The overall 12-year survival in these young adults is 93.1% (95% CI: 88.3–98.0), 99% in males and 87.3% in females. These survivorship data are superior to registry reported figures of THA amongst young patients and correspond well with previous reports from designer centres. The long-term survivorship and clinical outcome of the BHR are excellent in men, uninfluenced by preoperative diagnosis or age. However, survivorship in women is inferior and usually related to increased wear and reactions to metal debris. Malpositioning of components with associated wear-induced soft tissue fluid collections is the most frequent factor leading to failure of a HRA. In our experience, mid-term outcome following revision is good and complication and re-revision rates can be low. Surgical experience, early intervention in cases of mal-positioned implants, clinical use of ion levels, implantation of larger ceramic-on-ceramic THA femoral heads and patient education are factors in improving outcome and reducing complication and re-revisions following HRA revision.
Metal-on-metal hip resurfacing arthroplasty (MoMHRA) is a surgical option in the treatment of end-stage hip disease. The measurement of systemic levels of metal ions gives an insight into the wear occurring and is advocated by regulatory bodies as routine practice in the assessment of resurfaced hips. However, the acceptable upper levels of Chromium (Cr) and Cobalt (Co) ions concentration with clinical significance still have to be established. The aim of this study is to address this issue in unilateral and bilateral resurfaced hips. 453 patients with unilateral MoMHRA and 139 patients with bilateral MoMHRA at >12 months postoperative were retrospectively identified from an independent hip specialist's database. Routine metal ion levels were measured at last follow-up (ICPMS protocol). Radiological assessment included measurement of acetabular component orientation using EBRA, calculation of contact patch to rim (CPR) distance, and evaluation for any adverse X-ray findings. The cohort was divided into the well functioning group (Group A) and the non-well functioning group (Group B). A well functioning resurfacing gad to fulfil all of the following criteria (bilateral patients had to fulfil criteria for both hips): no patient reported hip complaints, no surgeon detected clinical findings, HHS> 95, CPR distance> 10mm, no abnormal radiological findings and no further operation scheduled. Upper levels (acceptable limits) of Cr/Co were considered to be represented by the top margin of the box-whisker plot [upper limit = 75th quartile value + (1.5 x interquartile range)] in Group A.INTRODUCTION
METHODS
Surface arthroplasty or resurfacing represents a significant development in the evolution of hip replacement. A hip resurfacing arthroplasty (HRA) is a bone conserving alternative to total hip arthroplasty (THA) that restores normal joint biomechanics and load transfer and ensures joint stability. Metal-on-metal (MoM) bearings have been preferred for these large diameter articulations because of their lower volumetric wear and smaller particulate debris compared to metal-on-poly-ethylene bearings. Of the many engineering factors which have contributed to the success of the MoM bearing, the metallurgy, diametral clearance, sphericity and surface finish were thought to be most important. More recently, adverse reactions to metal particles and ions generated by wear and corrosion of the metal surfaces have focused the attention on the importance of coverage angle and cup positioning. Currently, the scientific consensus is that cup coverage angle, diametral clearance and metallurgy have their importance in that order. Precise understanding of manufacturing variables is imperative in obtaining clinical consistency and safety in the patient. It is important to examine femoral fixation, bone remodelling, and wear of MoM implants. For the second and third generation MoM HRA various designs and biomaterials have been used. We have conducted a randomised, controlled trial comparing 9 different hip resurfacing prostheses. Clinical and radiographic outcome and whole blood, serum and urine metal ion levels are evaluated at 6 months, 1 year and 2 years in 180 patients with 9 different HRA designs and the differences are analyzed. Besides, the design quality of the 9 different metal-on-metal prostheses and their accessory instruments have been judged during the operation. The Durom with its Metasul history may claim a metallurgic advantage, and in combination with the highest coverage angle of all cups, it may be the best wear couple, as suggested by low ion measurements. However, as discussed above, an optimal bearing alone is not sufficient to achieve a successful hip resurfacing.
Tribological studies have described a characteristic wear pattern of metal-on-metal hip resurfacings (MoMHRAs) with a run-in period followed by a ‘bedding-in’ phase minimising wear or by an increasing wear patch with edge loading. The use of metal ions as surrogate markers of in-vivo wear is now recommended as a screening tool for the performance of MoMHRAs. The aims of this retrospective, single-surgeon study were to measure ion levels in unilateral MoMHRAs at different stages during the steady-state in order to study the evolution of wear and factors affecting it. 218 consecutive patients with minimum two serum ion measurements were included. The mean age at surgery was 52.3 years, the first assessment was made at a mean of 2.5 years (11 months–8 years) and the last assessment at a mean of 4.6 years post resurfacing (2– 12 years). Ion level change was defined as Ion level at last assessment minus Ion level at first assessment. Ten different resurfacing designs were implanted, the majority being BHR (n=104), Conserve plus(n=55) and ASR (n=25). The median femoral component size was 50 mm (38–59mm). Radiological assessment of acetabular component orientation was made with EBRA.Introduction
Methods
Bearing diameter and acetabular component orientation have been shown to be important variables effecting blood metal ion levels following hip resurfacing arthroplasty. So far no studies on bilateral hip resurfacings have taken into account these variables. We examined the serum ion results of patients under the care of two experienced hip resurfacing surgeons who carry out ion analysis as part of routine post operative care. Surgeon 1: Patients were implanted exclusively with a “third generation” resurfacing device. Surgeon 2: Patients were implanted with the same “third generation” device and also a low clearance “fourth generation” resurfacing device. Only ion results from patients who were 12 months post surgery were included. Bilateral patients were matched to unilateral patients according to the surgeon performing the operation; the resurfacing system implanted and cup inclination and anteversion angles. The ion data from each bilateral group was tested against the corresponding unilateral groups using the Mann Whitney U test for non parametric data. Significance was drawn at p<0.05. Surgeon 1: There were 310 patients with unilateral joints and 50 with bilateral joints. There were no significant differences with regard to time to follow up, activity levels, joint sizes or cup orientations. Serum chromium (Cr) and cobalt (Co) concentrations were significantly greater in the bilateral group (p<0.001). Median ion levels were greater in the bilateral group by a factor of >2 in the smallest joint sizes and <2 in the largest joints. Surgeon 2: There were 11 patients with bilateral third generation resurfacing joints and 50 with unilateral joints of the same design. The same relationship as described above was identified. There was a notable difference in the fourth generation implant group (n=13 bilateral, n=100 unilateral). Median ion levels for patients receiving bilateral joints of sizes <47mm were ten times greater than in the corresponding unilateral group. Bearing diameter and component design are critical factors in determining metal ion levels following bilateral hip resurfacings. Surgeons must consider the potential implications of gross increases in metal ion levels prior to performing bilateral hip resurfacings in smaller patients.
